92Bio Initiates Phase 1 Trial for Bispecific Antibody NTB-928 in Platinum-Resistant Ovarian Cancer
92Bio has announced that it has dosed the first patient in its Phase 1 clinical trial of NTB-928, a FOLR1×CD3 bispecific T-cell engager, for patients with platinum-resistant ovarian cancer. This development marks a significant milestone in advancing new therapeutic approaches for a highly challenging form of ovarian cancer. NTB-928 is precisely engineered to specifically target tumor cells while minimizing off-target side effects on healthy tissues.
Mechanism of Action and Unique Selectivity of NTB-928
NTB-928 is a bispecific antibody designed to simultaneously target Folate Receptor Alpha (FOLR1) and the CD3 receptor on T-cells. While FOLR1 is known to be overexpressed on the surface of ovarian cancer cells, it is also expressed on certain normal tissues (such as the kidney), leading to a significant challenge of “on-target, off-tumor toxicity” with conventional FOLR1-targeted therapies.
To overcome this, NTB-928’s binding characteristics have been optimized to activate T-cells only when FOLR1 expression levels are high on tumor cells. This design aims to efficiently recruit T-cells to FOLR1-overexpressing ovarian cancer cells, leading to their specific killing, while minimizing impact on normal tissues. This enhanced selectivity is crucial for improving the drug’s safety profile and maximizing therapeutic efficacy.
Background and Unmet Medical Needs
Ovarian cancer remains the deadliest gynecological malignancy, and treatment options become severely limited once the disease becomes platinum-resistant. Patients in this setting face a poor prognosis, necessitating the urgent development of effective therapies with novel mechanisms of action. Bispecific T-cell engagers like NTB-928 offer a distinct approach by leveraging the patient’s own immune cells to combat tumors, potentially bringing new hope to patients with refractory ovarian cancer.
Future Outlook
The Phase 1 clinical trial of NTB-928 will primarily evaluate its safety, tolerability, and pharmacokinetic profile. Initial efficacy signals will also be explored. The success of this trial is an essential factor in establishing a new therapeutic paradigm for platinum-resistant ovarian cancer. 92Bio anticipates that NTB-928 will overcome the limitations of previous FOLR1-targeted therapies and provide a safer and more effective treatment for patients, with future trial results keenly awaited by the oncology community.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments